Advances in Breast Cancer Research

Transcription

1 Other B01 B cell lymphoma 9 mediates a cross talk between the canonical Wnt and EGFR signaling in breast cancer. Hanan Elsarraj, Hong Yan, Jennifer Knapp, Anna Tsimelzon, Shixia Huang, Andrew Godwin, Sue Hilsenbeck, Dean Edwards, Fariba Behbod. B02 Complex molecular-scale dynamics of HER2 receptor transport in live SKBR3 breast cancer cells revealed by nanoscale quantum dot imaging. Wai Yan Lam, Yi Wang, Mark J Olah, Keith A Lidke, Marcel Bruchez, Joe Gray, Tania Q Vu. Targeted Therapies B03 A small-molecule antagonist of CX3CR1 impairs homing and colonization of breast cancer cells in the skeleton. Fei Shen, Yun Zhang, Danielle Jernigan, Jie Yan, Fernando Garcia, Olimpia Meucci, Joseph Salvino, Alessandro Fatatis. B04 Systemic delivery of silver nanoparticles and targeting of the folate receptor alpha for the treatment of triple-negative breast cancer. Jessica L Swanner, Cale D Fahrenholtz, Ravi N Singh. B05 Self-assembling platinum-acridine loaded carbon nanotubes for triple-negative breast cancer chemotherapy. Cale D Fahrenholtz, Song Ding, Brian W Bernish, Mariah Wright, Ulrich Bierbach, Ravi N Singh. B06 CDK7: A marker of poor prognosis and tractable therapeutic target in triple-negative breast cancer. Bo Li, Triona Ni Chonghaile, Yue Fan, Rut Klinger, Aisling E O'Connor, Emer Conroy, Finbarr Tarrant, Gillian O'Hurley, Girish Mallya Udupi, Alexander Gaber, Suet-Feung Chin, Helen A Bardwell, Philip C Schouten, Thierry Dubois, Sabine Linn, Karin Jirstrom, Carlos Caldas, Rene Bernards, Darran P O'Connor, William M Gallagher. B07 Mcl-1-mediated resistance to ABT-263 is combated by mtor inhibition in luminal breast cancers. Michelle M Williams, Linus Lee, Meghan M Morrison, Courtney McKernan, Violeta Sanchez, Donna Hicks, Thomas Stricker, Rebecca S Cook. B08 ESR1 coregulator binding site inhibitors (ECBIs) as novel therapeutics to target hormone therapy resistant breast cancer. Ratna K Vadlamudi, Gangadhara Reddy Sareddy, Suryavathi Viswanadhapalli, Tae-Kyung Lee, Shi-Hong Ma, Wan Ru Lee, Monica Mann, Samaya Rajeshwari Krishnan, Vijay Gonugunta, Douglas W Strand, Rajeshwar Rao Tekmal, JungMo Ahn, Ganesh V Raj. B09 Robotic mammosphere assay for high-throughput screening of cancer stem cell inhibitory drugs in triple-negative breast cancer. Paul A Fitzpatrick, Eamon Hughes, Göran Landberg. B10 mtorc1 directly phosphorylates and activates ERα upon estrogen stimulation. Anya Alayev, Marina K. Holz.

2 B11 A dual PI3K/mTOR inhibitor, BEZ235 blocks tumor-induced angiogenesis: Evidence for an effect on the tumor and endothelial compartment. Pradip De, Yuliang Sun, Jennifer H Carlson, Xiaoqian Lin, Nandini Dey, Brian Leyland-Jones. B12 Co-targeting PTEN-defined TNBC with p110beta-isoform specific inhibitor and PARP inhibitor BMN 673: A predictive context to sensitize PARP inhibitors in TNBC. Nandini Dey, Jennifer H Carlson, Pradip De, Brian Leyland-Jones. B13 Targeting the TGF-β pathway in breast cancer: Insights from preclinical studies. Yu-an Yang, Kathleen Flanders, Jin-qui Chen, Anand S Merchant, Howard Yang, Maxwell P Lee, Lalage M Wakefield. B14 Targeting the intratumoral heterogeneity of receptor tyrosine kinases in breast cancer. Elizabeth A Tovar, Erik S Linklater, Curt J Essenburg, Zach Madaj, David M Cherba, Mary E Winn, Hasan Korkaya, Julie L Boerner, Carrie R Graveel. B15 Semaphorin 7a exerts pleiotropic effects to promote breast tumor progression. Sarah Black, Andrew Nelson, Natalia Gurule, Bernard Futscher, Traci R Lyons. B16 Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Shaokun Shu, Charles Lin, Housheng Hansen He, Robert Witwicki, Justin Roberts, Doris Tabassum, Yi Liang, Muhammad Ekram, Ernest Doherty, Jonathan Brown, Hisham Mohammed, Clive D'Santos, Michael McKeown, Christopher Ott, Jun Qi, Min Ni, Prakash Rao, Melissa Duarte, Shwu-Yuan Wu, Cheng-Ming Chiang, Richard Young, Jason Carroll, Henry Long, Myles Brown, Shirley X. Liu, Clifford Meyer, James Bradner, Kornelia Polyak. B17 Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in MMTV-neu transgenic model. Yoshiko Shimizu, Hideki Furuya, Paulette M Tamashiro, Steve Goodison, Owen Chan, Ian Pagano, Kayoko Iino, Rafael Peres, Kanani Hokutan, Lenora W.M. Loo, Brenda Hernandez, Aung Naing, Charles J Rosser, Toshihiko Kawamori. B18 MEK inhibition in chemoresistant triple-negative breast cancer. Karina Julia Matissek, Andrew William Schultz, Lei He, Kenneth Ross, Elena Edelmann, Steven Jay Isakoff, Sridhar Ramaswamy, Leif William Ellisen. B19 MET and IL6 signaling in triple-negative breast cancer. Elizabeth A Tovar, Mansoureh Sameni, Curt J Essenburg, Anita Chalasani, Erik S Linklater, David M Cherba, Aruselvi Anbalagan, Mary E Winn, Bonnie F Sloane, Carrie R Graveel. B20 Combination of Ganoderma lucidum extract and erlotinib decreases IBC progression. Tiffany J Rios-Fuller, Ivette J Suarez-Arroyo, Mercedes Lacourt-Ventura, Geronimo Maldonado, Luis A Cubano, Michelle M Martinez-Montemayor. B21 Suppression of adaptive resistance mechanisms to trametinib by inhibition of BET bromodomains in TNBC. Samantha M Miller, Jon S Zawistowski, Timothy J Stuhlmiller, Noah Sciaky, Charlene M Santos, David B Darr, Gary L Johnson. B22 PSMD2 is a molecular marker for a poor prognosis and determines cancer stem cells traits in breast cancer. Kyung-Min Lee, So-Youn Jung, Seolwha Jo, Eunji Kang, Dong-Young Noh, Wonshik Han.

3 B23 Citral reduces ALDH1A3 activity in breast cancer: Potential applications in targeting breast cancer stem cells. Margaret L Thomas, Krysta M Coyle, Brianne Cruickshank, Michael Giacomantonio, Melissa Wallace, Carman Giacomantonio, Paola Marcato. B24 Triple-negative breast cancer adaptive response to MEK inhibition is regulated by the induction of super-enhancers. Jon S Zawistowski, Samantha M Miller, Daniel R Goulet, Timothy J Stuhlmiller, Darshan Singh, Noah Sciaky, Sara H Velarde, Steven P Angus, Gary L Johnson. B25 BET bromodomain inhibition targets adaptive responses to lapatinib in HER2-positive breast cancer. Timothy J. Stuhlmiller, Samantha M. Miller, Jon S. Zawistowski, James S. Duncan, Steven P. Angus, Deborah A. Granger, Rachel A. Reuther, Kyla A.L. Collins, Gomez M. Shawn, Pei-Fen Kuan, Xin Chen, Noah Sciaky, Gary L. Johnson. B26 Identification of genes that predict response to paclitaxel in breast cancer using an in vivo genome-wide knockdown screen. Mohammad Sultan, Thomas Tan Huynh, Margaret Lois Thomas, Krysta Mila Coyle, Carman A Giacomantonio, Paola Marcato. B27 Targeting of phosphatidylserine by monoclonal antibody ch1n11 enhances the antitumor activity of immune checkpoint inhibitor PD-1/PD-L1 therapy in orthotopic murine breast cancer models. Michael J Gray, Jian Gong, Van Nguyen, Michaela Schuler-Hatch, Chris Hughes, Jeff Hutchins, Bruce Freimark. B28 Activating mutations in PIK3CB confer resistance to PI3K inhibition in PTEN-deficient breast cancer and define a novel oncogenic role for p110β. Yoshito Nakanishi, Kimberly M Walter, Jill M Spoerke, Carol O'Brien, Ling Y Huw, Garret M Hampton, Mark R Lackner. B29 Anti-breast cancer effects of the Vav/Rac inhibitor Ehop-016 in the tumor microenvironment. Linette Castillo-Pichardo, Cristina Del Valle, Jessica Morales, Valance Washington, Krizia Rohena-Rivera, Magaly Martinez, Luis Cubano, Suranganie Dharmawardhane. B30 Ex vivo culture of breast cancer patient-derived xenografts in modified 3-D hyaluronan hydrogels. Lindsey K Sablatura, MeghaShyam Kavuri, Priya Richards, Daniel A Harrington, Matthew J Ellis, Mary C Farach-Carson. B31 LncRNA AK as a therapeutic target in aggressive breast cancers. Maneesh Kumar, Rebecca Sinnott DeVaux, Marcel E Dinger, John S Mattick, Charles M Perou, Jeffrey M Rosen, Sendurai A Mani, Jason I Herschkowitz. B32 Microenvironmental distribution of trastuzumab in metastases and xenograft models is highly heterogeneous and decreases sharply when administered in combination with bevacizumab. Jennifer H.E. Baker, Alastair H Kyle, Jordan Cran, Haley Patrick, Maria-Jose Gandolfo, Andrew I. Minchinton. B33, PR02 The spliceosome is a therapeutic vulnerability in MYC-driven breast cancer. Tiffany Hsu, Lukas Simon, Nicholas Neill, richard marcotte, Azin Sayad, Kristen Karlin, Chandraiah Lagisetti, Thomas Cooper, Thomas Webb, Benjamin Neel, Chad Shaw, Thomas ("Trey") Westbrook.

4 B34 PIM kinase as a novel therapeutic target for triple-negative breast cancer. Dai Horiuchi, Alicia Y Zhou, Alexandra N Corella, Christina Yau, Sanjeev Balakrishnan, Kai Kessenbrock, Devon A Lawson, Roman Camarda, Brittany N Anderton, Alexey V Bazarov, Henok Eyob, Julia Rohrberg, Paul Yaswen, Michael T McManus, Hope S Rugo, Zena Werb, Andrei Goga. B35 Concurrent use of alisertib and vaccinia virus demonstrate increased in vitro efficacy against breast cancer models with elevated numbers of cancer stem-like cells. Malgorzata Gil, Marcin Komorowski, Danuta Kozbor, Mateusz Opyrchal. B36 Inhibition of the autocrine IL-6-JAK2-STAT3-Calprotectin axis as targeted therapy for HR- /HER2+ breast cancers. Ruth Rodriguez-Barrueco, Jiyang Yu, Andrea Califano, jose silva. B37 Overcoming resistance to chemotherapy using ZNF217 as a predictive marker and therapeutic target of breast cancer. Christopher Suarez, Joseph Sparano, Sunil S. Badve, Laurie E. Littlepage. B38 Biosynthesized magnetic nanoparticles for specific targeting of breast cancer cells. John D Obayemi, Olushola S Odusanya, Karen A Malatesta, Winston O Soboyejo. B39 A novel analytical approach to accurately assess in vitro drug responses for breast cancer therapy. Mario Niepel, Marc Hafner, Peter K Sorger. B40 Transcription factor Snail mediates EMT by altering vesicular trafficking protein Rab25. Shreya Mitra, Lorenzo Federico, Gordon B Mills. B41 HGFL-Ron signaling enhances breast cancer stem cell populations. Sasha J Ruiz-Torres, Susan E Waltz. Trials in Progress B42 Ibrutinib in combination with durvalumab (MEDI4736) in patients with relapsed or refractory HER2-positive or triple-negative breast cancer: A phase 1b/2 multicenter study. Drew W. Rasco, Erkut Borazanci, Martin Guiterrez, David Hong, Ahmed Tawashi, Jennifer Lin, Isaiah W. Dimery, Mark Fosdale. Tumor Heterogeneity (Intratumor and Intertumoral) B43 APOBEC3B upregulation by the PKC-NFκB pathway in breast cancer. Brandon Leonard, Jennifer McCann, Gabriel Starrett, Leah Kosyakovsky, Molan Amy, Michael Burns, Rebecca McDougle, Peter Parker, William Brown, Reuben Harris.

5 B44 Clinical relevance of androgen and estrogen receptors in patients with ductal carcinoma in situ of the breast treated with surgery and radiotherapy. Sara Bravaccini, Sara Ravaioli, Maria Maddalena Tumedei, Rosella Silvestrini, Flavia Foca, Ilaria Massa, Roberta Maltoni, Andrea Rocca, Secondo Folli, Federico Buggi, Annalisa Curcio, Maurizio Puccetti, Luigi Serra, Elisabetta Pietri, Daniele Andreis, Alberto Farolfi, Dino Amadori. B45 De novo generation of highly aggressive human breast tumors by rapid serial passaging of oncogene-transduced starting populations of purified normal cells. Sylvain Lefort, Davide Pellacani, Long Nguyen, Connie J Eaves. B46 EMT-inducing transcription factors Twist1, Snail1 and Six1 increase metastasis of neighboring tumor cells via induction of Hedgehog-Gli signaling. Deepika Neelakantan, Hengo Zhou, Joshua Cabrera, Heide Ford. B47, PR05 The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ. Michalina Janiszewska, Lin Liu, Vanessa Almendro, Yanan Kuang, Cloud Paweletz, Britta Weigelt, Rita A. Sakr, Tari A. King, Sarat Chandarlapaty, Jorge S. Reis-Filho, Ariella B. Hanker, Carlos L. Arteaga, Park So Yeon, Franziska Michor, Kornelia Polyak. B48 Intratumor ploidy heterogeneity as a chemoresistance mechanism in triple-negative breastcancer. Rekha Gyanchandani, Adrian Lee. B49 Intratumor heterogeneity defines subtypes of HER2+ breast cancer with clinical implication. Inga Hansine Rye, Anne Trinh, Anna Sætersdal, Daniel Nebdal, Ole Christian Lingjærde, Vanessa Almendro, Kornelia Polyak, Anne-Lise Børresen-Dale, Florian Markowetz, Åslaug Hellan, Hege G Russnes. B50, PR06 Modeling the tumor microenvironment to identify novel loss of function mutations in breast cancer progression. Barrie Peck, Sarah Maguire, Eamonn Morrison, Patty Wai, Rachael Natrajan. B51 Modeling the intrinsic and extrinsic influences on breast cancer phenotypic heterogeneity using mouse models and three-dimensional bioprinting. Ellen M Langer, Xiaoyan Wang, Juan Liang, Brittany L Allen-Petersen, Nicholas D Kendsersky, Tyler Risom, Carl Pelz, Rosalie C Sears. B52 Overcoming phenotypic heterogeneity and plasticity in basal-like breast cancer through targeting adaptive pathway use. Tyler Risom, Ellen Langer, Juha Rantala, Mariano Alvarez, Katie Johnson- Camacho, Carl Pelz, Nicholas Wang, Paul Spellman, Andrea Califano, Joe Gray, Rosalie Sears. B53 Genomic redefinition of Her2+ breast shows role of estrogen and androgen signaling. Anneleen Daemen, Jacob Rinaldi, Gerard Manning. B54 Location of tumor burden influences tumor and vascular architecture, necrosis, and nanoparticle delivery. Jessica Kalra, Jennifer Baker, Alastair Kyle, Andrew Minchinton, Marcel Bally.

6 Tumor Microenvironment and Immunotherapy B55 Suppression of CD8 T-cell activation by tryptophan catabolism in triple-negative breast cancer. Lisa I Greene, Tullia C Bruno, Thomas J Rogers, Jill E Slansky, Virginia F Borges, Jennifer K Richer. B56 Prolactin promotes breast cancer to bone metastasis and breast cancer cell-mediated osteoclast differentiation. Amanda Forsyth, Ashley Sutherland, Yingying Cong, Laurel Grant, Tzu-Hua Juan, Jae K Lee, Alexander Klimowicz, Stephanie K Petrillo, Jinghui Hu, Angela Chan, Florence Boutillon, Vincent Goffin, Cay Egan, Patricia A Tang, Li Cai, Don Morris, Anthony Magliocco, Carrie S Shemanko. B57 Assessment of gene expression of calcium pumps, channels, and channel regulators in human breast cancer-associated fibroblasts. Teneale A Stewart, Patsy S Soon, Patsy S Soon, Patsy S Soon, Sarah J Roberts-Thomson, Gregory R Monteith. B58 Inflammatory signaling regulates osteoprotegerin expression in breast cancer cells. Stephanie Tsang Mui Chung, Ashleigh Renaud, Kim Roseman, Nalani Yadav, Linda Connelly. B59 Age and estrogen-dependent inflammation in breast adenocarcinoma and normal breast tissue. David A Quigley, Andliena Tahiri, Torben Lüders, Margit H Riis, Allan Balmain, Anne-Lise Børresen- Dale, Ida R Bukholm, Vessela Kristensen. B60 The clinical significance and molecular features of the spatial tumor shapes in breast cancers. Hyeong-Gon Moon, Namshin Kim, Minju Lee, HyunHye Moon, Tae-Kyung Yoo, Han-Byoel Lee, Jisun Kim, Dong-Young Noh, Wonshik Han. B61 Exosome transfer from stromal to breast cancer cells activates noncoding RNA sensing to regulate therapy resistance pathways. Barzin Y Nabet, Yu Qiu, Bihui Xu, Tony J Wu, Andy J Minn. B62 A novel combination HER2, brachyury, and MUC1 adenovirus based vaccines for a multitargeted immunotherapy approach to treat breast cancer. Yvette Latchman, Adrian Rice, Joseph Balint, Elizabeth Gabitzsch, Jeffrey Schlom, Frank Jones. B63 The utility and mechanistic basis of CTLA-4 and PD-1 immunotherapeutic checkpoint inhibitors in enhancing tumor-specific adaptive responses to effectively treat triple-negative breast cancer. Erika Crosby, Jun-Ping Wei, Xiao-Yi Yang, Gangjun Lei, Tao Wang, H Kim Lyerly, Zachary C Hartman. B64 Macrophage-specific deletion of STAT5 disrupts normal mammary gland development and accelerates mammary tumorigenesis. Nicholas J Brady, Michael A Farrar, Kathryn L Schwertfeger. B65 Live-cell imaging of 3D/4D parallel co-cultures of breast carcinoma cells and breast fibroblasts in tissue architecture and microenvironment engineering (TAME) chambers. Kyungmin Ji, Zhiguo Zhao, Kamiar Moin, Yong Xu, Bonnie F Sloane. B66 The immunoproteasome: A point of convergence between immune response chemokine signaling and metastasis in breast cancer. Alison M Anderson.

7 B67 CD4 Th1 cytokines synergize with HER-2/HER-3 blockade to induce tumor senescence and apoptosis in both HER-2 sensitive and resistant breast cancer cells. Cinthia Rosemblit, Brian J Czerniecki. B68 Contributions of STAT3 to pro-tumorigenic alterations within the microenvironment during mammary tumorigenesis. Polly Chuntova, Laura R Bohrer, Kaylee L Schwertfeger. B69 Acquisition and maintenance of anti-her2 target therapies resistance in breast cancer: Role of Fibrobroblasts. Patricia Fernandez-Nogueira, Mario Mancino, Gemma Fuster, Estel Enreig, Elisabeth Ametller, Paloma Bragado, Vanessa Almendro, Pere Gascon. Other B70 p16 and 9p21 deletion are largely unrelated but linked to unfavorable tumor phenotype in breast cancer. Patrick Lebok, Magdalena Roming, Martina Kluth, Christina Koop, Cansu Oezden, Brevian Taskin, Khakan Hussein, Anette Lebeau, Isabell Witzel, Sven Mahner, Stefan Geist, Peter Paluchowski, Christian Wilke, Uwe Heilenkoetter, Volkmar Mueller, Ronald Simon, Guido Sauter, Luigi Terracciano, Rainer Krech, Albert von der Assen, Eike Burandt.